Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensified insulin delivery using multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) is recommended in children with type 1 diabetes (T1D) to achieve good metabolic control. OBJECTIVE: To examine the frequency of pump usage in T1D children treated in SWEET (Better control in Paediatric and Adolescent diabeteS: Working to crEate CEnTers of Reference) centers and to compare metabolic control between patients treated with CSII vs MDI. METHODS: This study included 16 570 T1D children participating in the SWEET prospective, multicenter, standardized diabetes patient registry. Datasets were aggregated over the most recent year of treatment for each patient. Data were collected until March 2016. To assess the organization of pump therapy a survey was carried out. RESULTS: Overall, 44.4% of T1D children were treated with CSII. The proportion of patients with pump usage varied between centers and decreased with increasing age compared with children treated with MDI. In a logistic regression analysis adjusting for age, gender and diabetes duration, the use of pump was associated with both: center size [odd ratio 1.51 (1.47-1.55), P < .0001) and the diabetes-related expenditure per capita [odd ratio 1.55 (1.49-1.61), P < .0001]. Linear regression analysis, adjusted for age, gender, and diabetes duration showed that both HbA1c and daily insulin dose (U/kg/d) remained decreased in children treated with CSII compared to MDI (P < .0001). CONCLUSIONS: Insulin pump therapy is offered by most Sweet centers. The differences between centers affect the frequency of use of modern technology. Despite the heterogeneity of centers, T1D children achieve relatively good metabolic control, especially those treated with insulin pumps and those of younger age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 3×
“The prevalence of CSII therapy usage has increased in many countries, but there are still differences in CSII usage among countries.10 The overall use of insulin pumps in patients 0-18 y was 74% (2011) in Slovenia,7 and 58-65% (2015) in United States.15 The data from three large registries of pediatric type 1 diabetes…”
BackgroundInfluentialSelf-citationGlobal healthcare expenditure on diabetes for 2010 and 2030
Zhang, P., Zhang, X., Brown, J., Vistisen, D., Sicree, R., Shaw, J., & Nichols, G. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.01.026 · Cited by 1,145
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Self-citationMartin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2114 · Cited by 499
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009122.pub2 · Cited by 299 · cited 1×
“should be optimized as early as possible in the course of type 1 diabetes.(3) An intensified insulin regimen is necessary in T1D patients to achieve near-normal glucose control.”
BackgroundPurnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
(2015) · doi:10.1136/bmj.h3234 · Cited by 258
Lin, M. H., Connor, C. G., Ruedy, K. J., Beck, R. W., Kollman, C., Buckingham, B., Redondo, M. J., Schatz, D., Haro, H., Lee, J. M., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0132 · Cited by 81 · cited 1×
“onomic factors and low frequency of CSII usage was confirmed by other research.(22) In T1D therapy, systematic reviews of costeffectiveness showed a superiority of CSII over MDI.”
ResultRoze, S., Smith‐Palmer, J., Valentine, W., de Portu, S., Nørgaard, K., & Pickup, J. C. (2015) · Diabetic Medicine · doi:10.1111/dme.12792 · Cited by 77
Cited by
Karges, B., Schwandt, A., Heidtmann, B., Kordonouri, O., Binder, E., Schierloh, U., Boettcher, C., Kapellen, T., Rosenbauer, J., & Holl, R. W. (2017) · JAMA · doi:10.1001/jama.2017.13994 · Cited by 452
Self-citationAdvances in technology for management of type 1 diabetes
Beck, R. W., Bergenstal, R. M., Laffel, L. M., & Pickup, J. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31142-0 · Cited by 242
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
Self-citationvan den Boom, L., Karges, B., Auzanneau, M., Rami-Merhar, B., Lilienthal, E., von Sengbusch, S., Datz, N., Schröder, C., Kapellen, T., Laimer, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0345 · Cited by 191
“However, pump use varied considerably between regions (9,19,20) and centers, ranging from 0% to 90% (21).”
BackgroundResultSelf-citationISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Cardona-Hernandez, R., Schwandt, A., Alkandari, H., Bratke, H., Chobot, A., Coles, N., Corathers, S., Goksen, D., Goss, P., Imane, Z., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1674 · Cited by 129
Self-citationLin, M. H., Connor, C. G., Ruedy, K. J., Beck, R. W., Kollman, C., Buckingham, B., Redondo, M. J., Schatz, D., Haro, H., Lee, J. M., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0132 · Cited by 81
McTavish, L., Corley, B., Weatherall, M., Wiltshire, E., & Krebs, J. D. (2018) · Diabetic Medicine · doi:10.1111/dme.13576 · Cited by 34
Wersäll, J. H., Adolfsson, P., Forsander, G., & Hanas, R. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13377 · Cited by 21
Self-citationBratke, H., Margeirsdottir, H. D., Assmus, J., Njølstad, P. R., & Skrivarhaug, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01127-6 · Cited by 20
Metadata
- Authors
- Szypowska, A., Schwandt, A., Svensson, J., Shalitin, S., Cardona-Hernandez, R., Forsander, G., Sundberg, F., De Beaufort, C., Maahs, D., Maffeis, C., O‘Riordan, S. M. P., Krisane, I. D., Scharf, M., Castro, S., Konstantinova, M., Obermannova, B., Casteels, K., Gökşen, D., Galhardo, J., Kanaka-Gantenbein, C., Rami-Merhar, B., Madacsy, L., & the SWEET Study Group
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2016-07-15
- Volume
- 17
- Pages
- 38-45
- ISSN
- 1399-543X (ISSN-L)
- OpenAlex
- W2469275809
- Cited by
- 125
- References
- 9
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.